← Atlas Theme · spans 1 topics
Clinical breakthroughs cannot secure a market path if patients cannot tolerate the safety trade-offs.
Treatments carrying superior clinical and biological efficacy frequently face commercial and regulatory resistance if they trigger severe, intolerable toxicities or side effects.
1
Topics it spans
2
Findings citing it
—
Evidence window
The convergence
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Science & Health
Kailera and Hengrui's Oral GLP-1 Candidate HRS-7535 Hits Phase 3 Efficacy but Sparks GI Tolerability Concerns An oral GLP-1 therapy met its efficacy endpoints but suffered a severe setback as investors panicked over its intense, intolerable gastrointestinal side effects.
Science & Health
AstraZeneca and Ionis's Wainua Fails Pivotal Phase 3 CARDIO-TTRansform Heart Disease Trial Despite being safe, the drug’s high-stakes clinical trial failed entirely to show a functional advantage when evaluated alongside contemporary standard-of-care baseline treatments.